The FDA has granted priority review to brensocatib to treat patients with non-cystic fibrosis bronchiectasis, according to a ...
Patients with bronchiectasis in China have a high disease burden and a low rate of use of evidence-based treatments.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback